Tilaknagar Industries Ltd

- The company raised over Rs. 2,000 crore through a preferential allotment during the acquisition of Imperial Blue, duly approved by the Board and shareholders. - Debt of Rs. 2,100 crore was taken from banks and NBFCs with a principal moratorium for the first 2 years and balloon repayment at the end of tenure. - Warrants held by the promoter group will be converted in the upcoming fiscal year as part of the fundraising. - No specific mention of any new or future fundraising through debt or equity beyond these measures was made on the call. - The company is focused on integrating Imperial Blue and deleveraging the balance sheet, aiming to reduce net debt-to-EBITDA ratio below 1.0x by FY29.

- Prag distillery expanded facility is expected to be commissioned by end of Q4 FY26, targeting almost full utilization over the course of the year. - Approximately Rs. 10 crore of capital investment still pending related to Prag distillery. - License fees for Prag distillery have been fully paid. - The company plans increased A&P investment (advertising & promotion) as part of margin expansion strategy but has not provided specific percentages yet. - Post Imperial Blue acquisition, the company is entering into new bottling and vendor arrangements to ensure business continuity and minimal disruption during integration. - Focus on cost-saving initiatives and organizational restructuring to leverage synergies and expand market presence. - No explicit future strategic investment outside the Imperial Blue acquisition and associated integration is detailed, but organic launches of whisky brands in promising segments are planned.

- For FY26, Imperial Blue (IB) is expected to witness a low to mid-single digit volume degrowth compared to FY25 due to tepid performance prior to acquisition. - In Q4 FY26, despite integration, a high-single digit volume growth for IB is anticipated. - For FY27, the combined business expects high-single digit to low-double digit volume growth. - Beyond FY27, low-double digit volume growth is projected over the next couple of years. - Revenue growth is expected to be approximately 150-200 basis points above volume growth. - Overall, Q3 FY26 saw a 76.1% YoY volume increase to 5.3 million cases; excluding IB, volumes increased 16.8%. - The combined business targets EBITDA margin expansion of 150-250 basis points over the next 24-36 months.

- High-single digit volume growth expected for Imperial Blue (IB) in Q4 FY26. - Combined business volume growth guidance for FY27: high-single digit to low-double digit. - Beyond FY27: sustained low-double digit volume growth projected. - Revenue growth anticipated at approximately 150-200 basis points above volume growth for FY27 and onwards. - Consolidated EBITDA margins expected to expand by 150-250 bps over the next 24-36 months. - Margin expansion for acquired Imperial Blue business targeted at 250-350 bps over 24 months. - Net debt-to-EBITDA ratio projected to fall below 1.0x by FY29, indicating deleveraging. - Long-term return potential similar to past 5-7 years performance anticipated for shareholders. - Continuous focus on premiumization, new product development, and expanded distribution to drive profits and EPS growth.

The transcript does not explicitly mention any details regarding the current or expected order book or pending orders for Tilaknagar Industries. However, some relevant operational and strategic points related to business growth and integration include: - Successful acquisition and integration of Imperial Blue completed on November 30, 2025. - Expansion of distribution network, now covering a 200 million+ cases opportunity in the Indian alcobev market. - Expected high-single digit to low-double digit volume growth for combined business in FY27, progressing to low-double digit growth afterward. - Commissioning of expanded Prag bottling facility expected by Q4 FY26 to support operational scale-up. - Focus on margin expansion (150-350 bps) and deleveraging balance sheet over the next 2-3 years. - Continued organic product launches and brand revamps planned for growth and premiumization. No specific numbers or mentions of order backlog or pending orders were provided in the available transcript.